ArticleFrontiers in pediatrics2025
First retrospective study on pediatric nephrocalcinosis in Syria: clinical symptoms and causes.
Article in Frontiers in pediatrics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- [Ultrasound diagnosis of nephrocalcinosis in an infant with recurrent vomiting].Atencion primaria · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Nephrocalcinosis is the deposition of calcium oxalate and phosphate in the kidneys. It is often asymptomatic and diagnosed via ultrasound. Symptoms may include hematuria or sterile leukocyturia. Based on echogenicity, it is classified as medullary or cortical. Although it may pose a problem in developing countries, it has not been adequately studied in the Middle East. Objectives: To investigate the clinical manifestations and outcomes of nephrocalcinosis for the first time in Syria. And to establish a primary database for such studies in Syria and the Middle East region. Methods: This retrospective study was conducted in a single pediatric nephrology department of a tertiary university hospital in Damascus, Syria. We collected the medical records of patients with a primary diagnosis of nephrocalcinosis between January 2014 and January 2018. All clinical, laboratory examination, treatment, and follow-up information were collected and analyzed. Results: Among 75 patients Forty-one (54%) were males and 34 (46%) were females, the median age at presentation was 18 months. The most presenting symptom was incidentally found in 39% of cases, then failure to thrive in 32% of cases, and recurrent urinary tract infections in 10.5% of cases. The most common leading cause of nephrocalcinosis was metabolic disorders in 68% followed by tubulopathy in 20%. The cause of nephrocalcinosis remained unknown in 8%, and renal malformations for 4% of the cases. During the study, five children developed end-stage renal disease (ESRD), and fifteen children died from different causes. Conclusion: This is the first Syrian study to review nephrocalcinosis cases. The most common leading cause of NC was metabolic disorders, most importantly, the patient with progressive nephrocalcinosis must be convinced that a high daily fluid intake is the most valuable therapeutic option.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.